Subscribe to Search results

In a medical study conducted in 1981, Professor Thomas explained that future problems like liver cirrhosis were likely to arise as a result of hepatis.

Published on:

AIDS was first mentioned in the meetings of haemophilia centre directors in autumn 1982 when it was raised, almost as an afterthought, by Professor Bloom

Published on:

The 1981 annual returns were discussed at the meeting of haemophilia directors in autumn 1982.

Published on:

Estimated requirements for factor VIII was discussed at the meeting of haemophilia directors in autumn 1982

Published on:

Professor Bloom wondered what the value of giving the hepatitis B vaccine was when non-A, non-B seemed to be a bigger problem

Published on:

Dr Craske said he would find out more about AIDS following reports in the US and the possible relationship with blood products

Published on:

A summary of all the Annual Returns for UK Haemophilia Centres for the year 1981 were produced.

Published on:

The average amount of factor IX concentrate used per haemophilia B patient increased to 26,769 units at thr UK Haemophilia Centres.

Published on:

Dr Craske circulated a prospective study protocol. Any haemophilia centre directors could use the protocol when evaluating any new concentrate products; directors would be invited to report the results in a standardised way to the UKHCDs Hepatitis Working Party and to retain serial samples of each patient's serum so a collection would be available to evaluate any new marker tests for NANBH.

Published on:

The UKHCDs Hepatitis Working Party agreed that, as AIDS had similarities in its epidemiology to Hepatitis B, enquiries would be made by members of the Working Party to ascertain the likelihood of transmission by blood or blood products and a further meeting would be held when more information was available.

Published on:

Dr Rizza wrote that AIDS had caused a stir in the haemophilia world and one very senior physician had withdrawn his factor VIII concentrates from the accident room and insisted on vetting the patients himself before any dose was given. Dr Rizza felt that AIDS "should be looked at urgently if only to clear the air and dispel some of the apprehension that has been stirred up".

Published on:

Dr Craske sent a copy of his paper about AIDS to Dr Rizza and to Dr Ludlam

Published on:

Dr Craske thought it necessary to have a meeting of the Hepatitis Working Party "to decide what further investigations need to be undertaken in the British haemophiliac population".

Published on:

Dr Craske wrote to Dr Ludlam, enclosing a copy of the paper he prepared for the MRC Hepatitis Vaccine Working Group meeting, "which describes the most recent information available about [AIDS]".

Published on:

Dr Craske wrote to Dr Lane, enclosing a copy of the paper he prepared for the MRC Hepatitis Vaccine Working Group meeting, "which describes early information about AIDS in the U.S.A."

Published on:

Dr Dale Lawrence of the Centers for Disease Control in the United States wrote to Dr Craske about the US cases of AIDS among people with haemophilia.

Published on:

Dr Rizza wrote to Dr Lane to confirm arrangements made for an informal meeting to be held on 15 December 1982 at BPL to discuss hepatitis free/hepatitis reduced coagulant factor concentrate.

Published on:

Dr Cash wrote to Dr Lane expressing his view that it is not "in the best interests of the NHS Fractionation Centres, at this time, to encourage the commercial manufacturers to undertake clinical trials with a view to obtaining product licences."

Published on:

Alpha Pharmaceutical issued a press release, which said: "The evidence suggests, although it does not absolutely prove, that a virus or other disease agent was transmitted to them in the Factor VIII concentrate, derived from pooled human plasma."

Published on:

Cases of AIDS in haemophilia patients in the United States were discussed in a UK Haemophilia Centre Directors Hepatitis Working Party meeting. Among the issues raised was the possibility that Factor 8 or other blood products administered to haemophilia patients "might be implicated."

Published on: